Mucus penetrating gene carriers

• US 9,327,037 B2
• Filed: 02/08/2012
• Issued: 05/03/2016
• Est. Priority Date: 02/08/2011
• Status: Active Grant

• Current Assignee: Johns Hopkins University
• Original Assignee: Johns Hopkins University
• Inventors: Hanes, Justin Scot, Suk, Jung Soo
• Primary Examiner(s): Epps-Smith, Janet
• Application Number:
  US13/984,386
• Publication Number:
  US 20130323313A1
• Time in Patent Office: 1,546 Days
• Field of Search: 424/497, 424/94.6
• US Class Current: 1/1
• CPC Class Codes: A61K 47/20 containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
• CPC Class Codes: A61K 47/59 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61K 47/6935 the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
• CPC Class Codes: A61K 48/0041 the non-active part being polymeric
• CPC Class Codes: A61K 48/0075 characterised by an aspect of the delivery route, e.g. oral, subcutaneous
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: C12N 15/87 Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Abstract

Nanoparticles gene carriers, particularly nanoparticle gene carriers which exhibit increased rates of diffusion through cystic fibrosis (CF) mucus, as well as methods of making and using thereof, are described herein. The nanoparticle gene carriers are formed from a nucleic acid complexed to one or more biocompatible, polycationic polymers. The nanoparticle gene carriers also contain one or more mucus resistant polymers. In a particularly preferred embodiment, the nanoparticle gene carrier is a nanoparticle formed from one or more nucleic acids, PEI, and a mucus-resistant/diffusive graft copolymer composed of a PEI backbone functionalized by one or more PEG side chains. The nanoparticle gene carriers can efficiently diffuse through CF mucus, and can effectively serve as a vehicle to administer one or more nucleic acids to a patient suffering from CF.

Claims

1. A composition for delivery of nucleic acid comprising nanoparticles having an average diameter of between 5 and 500 nm, comprising

a) a complex formed by the ionic association of one or more nucleic acids and one or more polycationic polymers, and

b) one or more mucus-resistant/diffusive graft co-polymers non-covalently associated to the complex,

wherein the one or more mucus-resistant/diffusive graft co-polymers comprise a polycationic polymer backbone having multiple mucus-resistant/diffusive polymer side chains covalently attached thereto,

wherein the ratio of mucus-resistant/diffusive polymer side chains to the polycationic backbone is between 15:

1 and 60;

1, or wherein the one or more polycationic polymers and one or more mucus-resistant/diffusive graft co-polymers are present in a molar ratio of between 1;

5 and 5;

1, and

wherein the nanoparticles have a near neutral surface charge between about −

10 mV and about +10 mV.

2. The composition of claim 1 for delivery of nucleic acid to cystic fibrosis patients comprising:

a) a nucleic acid encoding a normal cystic fibrosis transmembrane conductance regulator (CFTR) or a nucleic acid complementary thereto, or a nucleic acid which repairs or replaces a defect in an abnormal CFTR gene,

b) polycationic polymer complexing to the nucleic acid, and

c) the cationic polymer-nucleic acid complex conjugated to or mixed with one or more mucus-resistant/diffusive polymers,

wherein the cationic polymer-nucleic acid complex forming nanoparticles have an average diameter of between 5 and 500 nm.

3. The composition of claim 1, wherein the nanoparticles are 300 nm or smaller.

4. The composition of claim 1, wherein the one or more mucus-resistant/diffusive polymers are polyalkylene oxide polymers or copolymers.

5. The composition of claim 3, wherein the polyalkylene oxide polymer is polyethylene glycol.

6. The composition of claim 4, wherein the polylalkylene oxide polymer comprises polyethylene oxide-polypropylene oxide block copolymers.

7. The composition of claim 1, wherein the one or more mucus-resistant/diffusive polymers have a molecular weight of between about 500 to 10,000 Daltons.

8. The composition of claim 7, wherein the one or more mucus-resistant/diffusive polymers have a molecular weight of between about 2,000 to 7,500 Daltons.

9. The composition of claim 1, wherein the polycationic polymer is selected from the group consisting of polyethyleneimine (PEI), polyarginine, polylysine, polyhistidine, and copolymers thereof.

10. The composition of claim 1, wherein the polycationic polymer has a molecular weight between 5000 and 50,000.

11. The composition of claim 1, wherein the polycationic polymer is conjugated to one or more mucus-resistant/diffusive polymers.

12. The composition of claim 11, wherein the mucus-resistant/diffusive polymer is a graft copolymer, having a polycationic backbone having multiple mucus-resistant/diffusive polymer side chains covalently attached thereto, wherein the ratio of mucus-resistant/diffusive polymer side chains to the polycationic backbone is between 20:

1 and 70;

1.

13. The composition of claim 1 wherein the nucleic acid is selected from the group consisting of DNA, RNA, stabilized nucleic acid encoding proteins, nucleic acid molecules complementary to the gene or nucleic acid molecule encoding proteins, and nucleic acid molecules correcting defects in the gene.

14. The composition of claim 1 further comprising one or more mucus degrading agents enhancing transport through the cystic fibrotic mucosa selected from the group consisting N-acetyl cysteine and rhDNase.

15. A method of treating a patient comprising administering an effective amount of the composition of claim 1 to a mucosal surface.

16. The method of claim 15 wherein the mucosal surface is in the pulmonary, ocular, nasal, buccal, vaginal, gastrointestinal, or rectal region.

17. The method of claim 15 wherein the formulation is administered to the pulmonary, nasal or buccal region using a nebulizer, dry particle inhaler, spray, aerosol inhalation, intranasal application, or intratracheal instillation.

18. The method of claim 15 where the patient has cystic fibrosis.